NFKB1 and cystic fibrosis: Thus, once biocompatibility issues are sufficiently addressed, pulmonary delivery of PEI along with decoy ONs against NF-κB may become an attractive therapeutic strategy for the treatment of complex lung pathologies (i.e., CF) requiring a multidrug approach aimed at controlling chronic inflammation, infection and iperproduction of a viscous mucus [19].